XML 115 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Information (Notes)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
20. Segment Information

In connection with its investment in Evofem in the second quarter of 2019, the Company added a fourth reportable segment, “Strategic Positions.” This had no impact on the Company’s prior segment reporting structure.

Information regarding the Company’s segments for the year ended December 31, 2019 and 2018 is as follows:
Revenues by segment
 
Year Ended December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Medical Devices
 
$
30,742

 
$
24,652

Strategic Positions
 
—

 
—

Pharmaceutical
 
55,093

 
80,796

Income Generating Assets
 
(31,078
)
 
92,662

Total revenues
 
$
54,757

 
$
198,110


(Loss) income by segment
 
Year Ended December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Medical Devices
 
$
(5,230
)
 
$
(5,086
)
Strategic Positions
 
28,758

 
—

Pharmaceutical
 
(19,048
)
 
(98,368
)
Income Generating Assets
 
(74,891
)
 
34,595

Total net (loss) income
 
$
(70,411
)
 
$
(68,859
)

Long-lived assets by segment
 
Year Ended December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Medical Devices
 
$
2,435

 
$
3,545

Strategic Positions
 
—

 
—

Pharmaceutical
 
2,960

 
3,682

Income Generating Assets
 
125

 
160

Total long-lived assets
 
$
5,520

 
$
7,387


The operations for the Medical Devices segment are primarily located in the United States and the operations for the Pharmaceutical segment are primarily located in Italy, Ireland and the United States.